CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Genmab A/S (GMAB) / epcoritamab
Forward catalyst · GMAB

epcoritamab

Sponsor Genmab A/S · listed as GMAB

READOUT Phase 3 Confidence: medium Source: clinicaltrials

epcoritamab is a clinical-stage drug asset sponsored by Genmab A/S, listed as GMAB. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2027 (month precision, medium confidence), tied to trial NCT05578976. The asset is in Phase 3 and currently active not recruiting, studied in Diffuse Large B-Cell Lymphoma. It appears across 6 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-06-30
As disclosedJun 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05578976
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorGenmab
Listed asGMAB
Condition(s)Diffuse Large B-Cell Lymphoma
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More GMAB catalysts